ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.730,36
-0,21%
S&P 500
5.738,17
-0,13%
US Dollar vs BRL
5,4341
-0,08%
Bitcoin
65.792,95
0,94%
Brent Oil
71,96
1,42%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. CytomX Therapeutics Inc (CTMX)

  7. CytomX Therapeutics Inc (CTMX) Notícias

CTMX

CytomX Therapeutics (CTMX)

CytomX Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CTMX
DataHoraFonteTítuloCódigoCompanhia
09/09/202409:00GlobeNewswire Inc.CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid TumorsNASDAQ:CTMXCytomX Therapeutics Inc
04/09/202409:00GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming September Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
22/08/202419:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
20/08/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CTMXCytomX Therapeutics Inc
09/08/202417:06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CTMXCytomX Therapeutics Inc
08/08/202417:10GlobeNewswire Inc.CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
08/08/202417:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTMXCytomX Therapeutics Inc
08/08/202417:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTMXCytomX Therapeutics Inc
01/08/202409:00GlobeNewswire Inc.CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024NASDAQ:CTMXCytomX Therapeutics Inc
18/06/202409:00GlobeNewswire Inc.CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
17/06/202417:15GlobeNewswire Inc.CytomX Therapeutics Promotes Chris Ogden to Chief Financial OfficerNASDAQ:CTMXCytomX Therapeutics Inc
22/05/202417:05GlobeNewswire Inc.CytomX Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
16/05/202417:15GlobeNewswire Inc.CytomX Therapeutics Announces New Employment Inducement GrantsNASDAQ:CTMXCytomX Therapeutics Inc
13/05/202417:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CTMXCytomX Therapeutics Inc
08/05/202417:10GlobeNewswire Inc.CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)NASDAQ:CTMXCytomX Therapeutics Inc
08/05/202417:10GlobeNewswire Inc.CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
07/05/202417:15GlobeNewswire Inc.CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)NASDAQ:CTMXCytomX Therapeutics Inc
01/05/202409:00GlobeNewswire Inc.CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024NASDAQ:CTMXCytomX Therapeutics Inc
08/04/202409:00GlobeNewswire Inc.CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid TumorsNASDAQ:CTMXCytomX Therapeutics Inc
03/04/202409:00GlobeNewswire Inc.CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasNASDAQ:CTMXCytomX Therapeutics Inc
21/03/202409:00GlobeNewswire Inc.CytomX Therapeutics Appoints Dr. Zhen Su to Board of DirectorsNASDAQ:CTMXCytomX Therapeutics Inc
18/03/202409:00GlobeNewswire Inc.CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202417:30Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202417:10GlobeNewswire Inc.CytomX Therapeutics Reports 2023 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202417:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CTMXCytomX Therapeutics Inc
11/03/202407:39IH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:CTMXCytomX Therapeutics Inc
04/03/202410:00GlobeNewswire Inc.CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024NASDAQ:CTMXCytomX Therapeutics Inc
27/02/202410:00GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
24/01/202410:00GlobeNewswire Inc.CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2bNASDAQ:CTMXCytomX Therapeutics Inc
12/01/202410:00GlobeNewswire Inc.CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CTMX

Seu Histórico Recente

EU
BE2141106259
Euronext VPU Public auct...
BMF
DIIF26F28
DIIF26F28 - 01/2026
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados